Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
June 3, 2021
Zhiqiang Ku, Xuping Xie, Paul R. Hinton, Xinli Liu, Xiaohua Ye, Antonio E. Muruato, Dean C. Ng, Sujit Biswas, Jing Zou, Yang Liu, Deepal Pandya, Vineet D. Menachery, Sachi Rahman, Yu-An Cao, Hui Deng, Wei Xiong, Kevin B. Carlin, Junquan Liu, Hang Su, Elizabeth J. Haanes, Bruce A. Keyt, Ningyan Zhang, Stephen F. Carroll, Pei-Yong Shi & Zhiqiang An.
Ku et al engineered IgM-14 to tackle antibody resistance portrayed by some viruses. IgM-14 is a neutralizing antibody. In their study, the research team found that IgG-14 was able to successfully neutralize the E484A and the K444R+E484A COVID-19 variants. In vivo, within living organism, protection against COVID-19 variants was also studied in mice. The researchers found that the IgM-14 protein was able to reduce viral loads by 16,429 and 144-fold against the P.1 variant. The study team has also found that the IgM-14 protein can be developed in high titters with reasonable purity and stability. The findings of the study showcases that the IgM-14 protein can hold future potential as a therapy option for patients infected with different variants of COVID-19.
Ku Z, Xie X, Hinton PR, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 2021; : 1–9.